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The pro-apoptotic BH3-only protein, BIK, is widely expressed and although many critical functions in developmental or stress-
induceddeathhavebeenascribedtothisprotein,micelackingBikdisplaynoovertabnormalities.IthasbeenpostulatedthatBik
can serve as a tumour suppressor, on the basis that its deﬁciency and loss of apoptotic function have been reported in many
human cancers, including lymphoid malignancies. Evasion of apoptosis is a major factor contributing to c-Myc-induced tumour
development, but despite this, we found that Bik deﬁciency did not accelerate El-Myc-induced lymphomagenesis. Co-operation
between BIK and NOXA, another BH3-only protein, has been previously described, and was attributed to their complementary
binding speciﬁcities to distinct subsets of pro-survival BCL-2 family proteins. Nevertheless, combined deﬁciency of Bik and
Noxa did not alter the onset of El-Myc transgene induced lymphoma development. Moreover, although p53-mediated induction
of Bik has been reported, neither El-Myc/Bik
 /  nor El-Myc/Bik
 / Noxa
 /  lymphomas were more resistant than control
El-Myc lymphomas to killing by DNA damaging drugs, either in vitro or in vivo. These results suggest that Bik, even in
combinationwithNoxa,isnotapotentsuppressorofc-Myc-driventumourigenesisorcriticalforchemotherapeuticdrug-induced
killing of Myc-driven tumours.
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Impaired apoptosis can allow abnormal survival of cells
undergoing neoplastic transformation, thereby facilitating the
accumulation of further oncogenic mutations.
1 In addition to
promoting the development of neoplastic disease, defects in
the apoptotic machinery can also impair the response of
tumour cells to various anti-cancer agents.
1
The BCL-2 regulated apoptotic pathway, triggered by
various damage signals, is controlled by interactions between
the pro- and anti-apoptotic members of the Bcl-2 protein
family. The pro-survival members, BCL-2, BCL-XL, BCL-W,
MCL-1 and A1, are essential for cell survival. The multi-BH
domain pro-apoptotic subfamily members BAX and BAK are
the critical effectors of apoptosis, responsible for mitochon-
drial outer membrane permeabilisation and consequent
cellular demolition. The pro-apoptotic BH3-only subfamily
members, including BIK/NBK/BLK, BAD, BID, HRK/DP5,
BIM, NOXA, BMF and PUMA, are activated by diverse
developmental signals and stress stimuli and act as cell-type-
and stimulus-speciﬁc cell death initiators. Different BH3-only
proteins have distinct speciﬁcities for binding pro-survival
BCL-2 proteins. BIM, BID and PUMA are ‘promiscuous’,
binding avidly to BCL-2 and all its pro-survival homologues,
whereas other BH3-only proteins, such as NOXA and BIK,
bind only to subsets of pro-survival proteins.
2 According to the
‘direct activation’ model, certain BH3-only proteins (called
‘activators’), such as BIM, BID and PUMA, can directly bind
and activate BAX/BAK.
3 Conversely, the ‘indirect model’ posits
that cell death is initiated when all pro-survival BCL-2 proteins
sequestering BAX/BAK are neutralised by BH3-only proteins,
thereby unleashing the pro-apoptotic actions of BAX/BAK.
4
BIK/BLK/NBK was identiﬁed in a screen for interactors with
BCL-2, BCL-XL or the viral analogue E1B19kD.
5,6 Although
Bik is widely expressed, mice lacking Bik display no overt
abnormalities.
7 Non-transformed hematopoietic cells and
ﬁbroblasts from BIK-deﬁcient mice respond normally to
apoptotic stimuli, such as treatment with DNA-damaging
chemotherapeutic drugs (e.g., etoposide) indicating that BIK
may have overlapping functions with other BH3-only proteins.
1Molecular Genetics of Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia;
2Department of Medical Biology, The
University of Melbourne, Parkville, Victoria, Australia and
3Department of Mathematics and Statistics, The University of Melbourne, Parkville, Victoria, Australia
*Corresponding author: CL Scott, Molecular Genetics of Cancer Division, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria
3052, Australia. Tel: +61 3 9345 2498; Fax: +61 3 9347 0852; E-mail: scottc@wehi.edu.au
Received 13.1.12; revised 21.2.12; accepted 29.2.12; Edited by P Salomoni
Keywords: Bik; Noxa; Myc; Bcl-2 family; BH3-only; apoptosis
Abbreviations: A1,B-celllymphoma2relatedproteinA1a;BCL-2,B-celllymphoma2;BCL-W,BCL-2-like2;BCL-XL,BCL-2like1;BH3,Bcl-2homology3;BAD,BCL-
2-associated agonist of cell death; BID, BH3-interacting domain death agonist; BIK, Bcl-2-interacting killer; BIM, BCL-2-like 11; BMF, BCL-2 modifying factor; CDKN2A,
cyclin-dependent kindase inhibitor 2A; cDNA, complementary DNA; CTX, cyclophosphamide; DNA, deoxyribose nucleic acid; HRK, harakiri; MCL-1, myeloid cell
leukaemia sequence 1; MEF, mouse embryonic ﬁbroblast; MDM2, p53 E3 ubiquitin ligase (mouse); mRNA, messenger RNA; NOXA, phorbol-12-myristate-13-acetate-
inducedprotein1;PUMA, p53upregulatedmodulator ofapoptosis; qRT-PCR,quantitativereverse-transcriptase polymerasechainreaction;QVD-OPH,broadspectrum
caspase inhibitor; RNA, ribonucleic acid; SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis; WT, wild-type
Citation: Cell Death and Disease (2012) 3, e306; doi:10.1038/cddis.2012.42
& 2012 Macmillan Publishers Limited All rights reserved 2041-4889/12
www.nature.com/cddisBIK is proposed to function as a tumour suppressor (see
review Chinnadurai et al.
8). Deletions in regions of chromo-
some 22q, encompassing the BIK gene, have been reported
in human colorectal as well as head and neck cancers and
gliomas. Loss of heterozygosity at the BIK locus has been
observed in renal cell carcinomas. Mutations within the BIK
gene were found in human B-cell lymphomas and microarray
analyses have revealed epigenetic silencing of BIK in multiple
myeloma-derived cell lines.
To assess the tumour suppressor potential of Bik, we have
examinedtheimpactofBikdeﬁciencyonlymphomagenesisin
Em-Myc transgenic mice, which develop pre-B or B-cell
lymphoma resulting from c-Myc overexpression followed by
acquisition of additional oncogenic mutations.
9,10 We found
that loss of Bik, even in combination with loss of Noxa (which
has a binding speciﬁcity complementary to Bik), did not
accelerate Em-Myc-induced lymphomagenesis.
BIK-induced apoptosis has mainly been demonstrated in
epithelial cancer-derived cell lines using in vitro overexpres-
sion systems.
5,6,11–16 The role of endogenous Bik in che-
motherapeutic drug-induced killing of cancer cells has not
been examined in detail. Curiously, reports have described
both p53-dependent
17,18 and p53–independent
19,20 transcrip-
tional induction of Bik in response to anti-cancer therapeutics
in human tumour-derived cell lines but the relevance of these
ﬁndings is unclear. We have previously shown that Bik loss
does not alter sensitivity of Em-Myc lymphoma cells with
functional p53 to apoptosis induced by etoposide in vitro.
21
We show here that neither loss of Bik alone, nor the combined
deﬁciency of Bik and Noxa, affect sensitivity of Em-Myc
lymphomas to the DNA-damaging chemotherapeutic drug,
cyclophosphamide (CTX) in vivo and demonstrate that loss of
Bik and Noxa can be adequately compensated for by other
BH3-only proteins in the response of lymphoma cells to DNA-
damaging chemotherapy.
Results
Bik is expressed in El-Myc lymphoma cells. c-Myc
overexpression upregulates the expression of the BH3-only
genes Noxa, Puma and Bim
22 and loss of these proteins was
shown to accelerate lymphomagenesis in Em-Myc transgenic
mice.
22–25 Similarly, pre-leukaemic B220
þ sIgM
  pre-B and
B220
þ sIg
þ B-lymphoid cells from pre-malignant Em-Myc
mice (4–6 weeks of age) displayed higher levels of Bik
mRNA induction (B5-fold and B17-fold increase, respec-
tively) compared with their counterparts from control (non-
transgenic, wt) littermates (Figure 1a). Bik is expressed in a
diverse range of haematopoietic cell types,
7 however, little
has been reported about its levels in neoplastic haemato-
poietic cells. Higher levels of Bik mRNA were observed in
Em-Myc pre-B lymphoma (B2-fold increase) and Em-Myc
B-lymphoma cells (B7-fold increase) isolated from sick (tumour-
bearing) Em-Myc transgenic mice compared with normal pre-B
and B-lymphoid cells from healthy C57BL/6 mice (Figure 1b).
Neither loss of Bik nor combined loss of Bik and Noxa
accelerate El-Myc lymphoma development. Bik is not
essential for normal mouse development and unstressed
Bik
 /  mice display no haematopoietic abnormalities
despite its widespread expression in the haematopoietic
compartment.
7 We examined the effect of BIK deﬁciency on
Em-Myc-induced lymphomagenesis. Em-Myc mice (n¼68)
displayed a median survival of 106 days and Em-Myc/Bik
 / 
(n¼30) mice succumbed at a similar rate with a median
survival of 109 (Em-Myc/Bik
 /  vs Em-Myc P¼0.433)
(Figure 2a). Severity of disease manifestation in Em-Myc/
Bik
 /  mice was comparable to that reported in control
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Figure 1 Bik mRNA levels are modestly increased in B-lymphoma cells and
pre-malignant lymphoid cells from Em-Myc mice compared with control B-lymphoid
cells. (a) Bik mRNA expression is increased in pre-neoplastic B-lymphoid cells and
(b) in lymphoma cells from sick Em-Myc mice. Differences in the levels of mRNA for
pro-apoptotic BH3-only genes between FACS-puriﬁed pre-B (B220
þ sIgM
 ) and
B (B220
þ sIgM
þ) cell subsets obtained from healthy 4–6-week-old Em-Myc mice
(a) or from sick lymphoma-bearing Em-Myc mice (b), compared with the
corresponding non-transformed pre-B and B-lymphoid cells from age-matched
control C57BL/6 mice. Relative RNA expression levels were calculated by
normalising to the b-actin signal in each sample, then dividing the values from the
Em-Myc transgenic B-lymphoid or -lymphoma cells by the value from the control
(nontransgenic)cells(representedbythedottedhorizontallineat1).Datarepresent
mean expression±S.E.M. of cells (lymphoma or control non-transformed) from
three individual mice of each genotype analysed in three separate experiments. In
pre-malignant Em-Myc B220
þ sIgM
þ B cells, the fold induction of Bik mRNA
compared with that observed in control nontransgenic B220
þ sIgM
þ B cells, was
signiﬁcantly higher (*Po0.05) than the fold induction of Bad, Bid, Bim and Noxa
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2
Cell Death and DiseaseEm-Myc mice
9,10 with conspicuous enlargement of lymph
nodes, spleen and thymus.
Given the complementary binding patterns of the BH3-only
proteins NOXA (MCL-1, A1) and BIK (BCL-2, BCL-XL, BCL-
W) to pro-survival BCL-2 family members
2,26 and the report
that, when enforcibly expressed, these two BH3-only proteins
can cooperate to induce BAX activation, resulting in mito-
chondrial release of cytochrome c,
15 we generated Em-Myc
mice doubly-deﬁcient for Noxa and Bik. As reported pre-
viously,
22 loss of Noxa did not signiﬁcantly affect Em-Myc-
induced lymphomagenesis with Em-Myc/Noxa
 /  mice dis-
playing a median survival of 133 days (n¼64) compared with
a median survival of 106 days in control Em-Myc mice (n¼68)
(Figure 2a). Even the combined loss of both Bik and Noxa did
not accelerate Em-Myc-induced lymphomagenesis (median
survival 100 days; n¼27; Figure 2a).
qRT-PCR analysis of Em-Myc/Bik
 /  and Em-Myc/Bik
 / 
Noxa
 /  lymphomas showed no signiﬁcant differences in
expression levels of the pro-apoptotic BH3-only genes Bad,
Bim, Bmf, Puma, Noxa, or of the pro-survival Bcl-2 family
genes, Bcl-2, Bcl-x, Mcl-1 when compared with control Em-
Myc lymphoma cells (Figure 3a). These results demonstrate
that loss of Bik, or even combined loss of Bik and Noxa, two
BH3-only proteins with complementary binding speciﬁcity for
Bcl-2-likepro-survivalproteins,doesnotcausecompensatory
upregulation of the other remaining BH3-only genes, or
changes in expression of pro-survival Bcl-2 genes at the
transcript level.
Loss of Bik alone, or in combination with Noxa loss has
no effect on disease severity or lymphoma subtype in
Em-Myc transgenic mice. Immunophenotyping of primary
lymphomas revealed that the majority were either B220
þ
sIgM
  pre-B lymphomas or B220
þ sIgM
þ B-cell lympho-
mas, whereas a small minority displayed a mixed population
of both sIgM
  and sIgM
þ lymphoma cells. The overall
proportions of pre-B and sIg
þ B-cell lymphomas were not
signiﬁcantly altered as a result of Bik deﬁciency (9/25 Pre-B,
14/25 B) or combined Noxa and Bik deﬁciency (10/16 pre-B
and 5/16 B), compared with control Em-Myc (9/21 pre-B,
11/21 B), and Em-Myc/Noxa
 /  (7/23 pre-B, 11/23 B) mice
(Figure 3b).
Differences in tumour onset depending on tumour immu-
nophenotypeinEm-MycmicelackingsingleBH3-onlyproteins
have been documented. Loss of BIM, PUMA, BMF or BAD
accelerated Em-Myc B-cell lymphoma development while the
onset of pre-B lymphomas was not altered.
22,23,25 These data
indicate that BH3-only proteins exert differentiation stage-
speciﬁc suppressive effects on lymphomagenesis and high-
light the necessity of analysing the impact of BH3-only protein
deﬁciencies on tumourigenesis, with respect to immunophe-
notype. Tumour onset in Em-Myc, Em-Myc/Bik
 /  and Em-
Myc/Bik
 / Noxa
 /  mice was therefore stratiﬁed according
to pre-B or B lymphoma subtype. No signiﬁcant differences in
survival were observed between Em-Myc/Bik
 /  mice bear-
ing pre-B (median survival 145 days, n¼9) or mature B cell
(median survival 128 days, n¼11) lymphomas versus control
Em-Myc mice bearing pre-B (median survival 202 days,
n¼10) or B cell (median survival 125 days, n¼14)
lymphomas (Figure 2b). Similarly, the survival of Em-Myc/
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Figure 2 Neither loss of Bik, nor combined loss of Bik and Noxa accelerate
lymphoma development in Em-Myc transgenic mice. (a) Kaplan–Meier survival
analysis of mice of the indicated genotypes. Differences in tumour onset between
Em-Myc (n¼68), Em-Myc/Noxa
 /  (n¼64), Em-Myc/Bik
 /  (n¼30) and Em-
Myc/Bik
 / Noxa
 /  (n¼27)micewerenotsigniﬁcant(P¼0.170,0.433,0.321,
respectively compared with control Em-Myc). (b) Loss of BIK alone, or in
combinationwithNOXAloss,inEm-Mycmicedidnotsigniﬁcantlyalterthelatencyor
incidence of either pre-B lymphomas (top panel; Em-Myc n¼10, Em-Myc/Bik
 / 
n¼9, Em-Myc/Bik
 / Noxa
 /  n¼10) or B lymphomas (bottom panel; Em-Myc
n¼14, Em-Myc/Bik
 /  n¼11, Em-Myc/Bik
 / Noxa
 /  n¼5) compared with
those seen in Em-Myc mice
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Cell Death and DiseaseBik
 / Noxa
 /  mice bearing pre-B or mature B-cell
lymphomas (median survival 117 days and 165 days,
respectively) did not differ signiﬁcantly from the survival of
control Em-Myc, Em-Myc/Bik
 /  or Em-Myc/Noxa
 / 
(median survival pre-B 134 days, B cell 104 days) lym-
phoma-bearing mice (Figure 2b).
Analysis of peripheral blood of sick Em-Myc/Bik
 / 
and Em-Myc/Bik
 / Noxa
 /  mice at death revealed no
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Figure 3 Loss of Bik or combined loss of Bik and Noxa does not alter lymphoma subtype or severity of disease in Em-Myc transgenic mice. (a) Differences in the levels
of mRNA for BCL-2 family members between FACS-puriﬁed B220
þ lymphoma cells harvested from either sick Em-Myc mice lacking Bik, lacking both Bik and Noxa,
or from sick control Em-Myc mice. qRT-PCR analysis was performed on cDNA and relative expression of RNA was calculated by normalising to the b-actin signal in
each sample, then dividing the value from the Em-Myc/Bik
 /  or Em-Myc/Bik
 / Noxa
 /  lymphoma cells by the value from the control Em-Myc lymphoma cells.
Datarepresentmeanexpression±S.E.M.oflymphomacellsfromthreeindividualmiceofeachgenotypefromthreeseparateexperiments.(b)Proportionsofpre-B(sIgM
 ),
B cell(sIgM
þ) andmixed pre-Band B-cell lymphomas insick Em-Myc,E m-Myc/Bik
 / ,Em-Myc/Noxa
 /  andEm-Myc/Bik
 / Noxa
 /  miceare shown. (c) Numbersof
white blood cells (WBC) and (d) numbers of lymphocytes in the peripheral blood of sick control Em-Myc, Em-Myc/Bik
 /  Em-Myc/Noxa
 /  and Em-Myc/Bik
 / Noxa
 / 
mice. (e) Spleen weights of sick, lymphoma-bearing Em-Myc,E m-Myc/Bik
 /  Em-Myc/Noxa
 /  and Em-Myc/Bik
 / Noxa
 /  mice. For (c–e), each dot represents a
single sick (lymphoma-burdened) animal and the mean is represented by a bar. Numbers of Em-Myc, Em-Myc/Bik
 /  and Em-Myc/Bik
 / Noxa
 /  mice included are
24, 28 and 23, respectively
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Cell Death and Diseasesigniﬁcant differences in leukaemic burden or lymphocyte
counts compared with sick control Em-Myc or Em-Myc/
Noxa
 /  mice (Figures 3c and d). Spleen weights from
Em-Myc/Bik
 /  mice at autopsy were signiﬁcantly, albeit
modestly (P¼0.02), greater than those observed for spleens
from control Em-Myc mice (Figure 3e). Histological examina-
tion of organs from sick Em-Myc/Bik
 /  and Em-Myc/
Bik
 / Noxa
 /  mice showed similar extent of tumour
inﬁltration into lymph nodes, spleen, thymus, liver, lung and
kidney to that seen in control Em-Myc mice (Figure 4,
Supplementary Table 1).
The incidence of p53 pathway mutations in El-Myc
lymphomas is not altered as a result of Bik deﬁciency or
combined deﬁciency of Noxa and Bik. There is signiﬁcant
pressure for the p19
ARF – p53 pathway to be compromised
during Em-Myc-induced lymphoma development.
27 Loss of
certain BH3-only proteins, such as BIM,
23,28 PUMA
22,24 or
BMF
25 can alleviate the need for p53 pathway mutations in
Em-Myc lymphomas. We detected no spontaneous deletions
of the p16
Ink4a/p19
Arf locus by genomic PCR in a panel of
randomly selected Em-Myc/Bik
 /  and Em-Myc/Bik
 / 
Noxa
 / 
lymphomas (Figure 5a).
As p53 normally regulates p19
ARF protein expression by a
negativefeedback loopinhealthy cells
27(Figure 5d), thelevels
of p19
ARF as well as p53 protein were examined by western
blotting in a panel of randomly selected Em-Myc/Bik
 / ,
Em-Myc/Bik
 / Noxa
 /  and control Em-Myc lymphomas.
In these assays high levels of p19
ARF indicate loss of p53
function because of impaired negative regulation;
29 and high
levelsofp53indicatemutant,stabilisedp53.Highp19
ARFand/
or p53 protein levels were detected in 3/20 (15%) Em-Myc/
Bik
 /  and in 3/10 (30%) Em-Myc/Noxa
 /  (Figures 5b and
c) lymphomas. This prevalence was comparable to that seen
in control Em-Myc lymphomas (2/15 (13.3%) as well as to the
previously published incidence of 3/10 (30%) in Em-Myc/
Noxa
 /  lymphomas.
22
p53-independent Bik induction occurs following DNA-
damaging drug treatment in El-Myc lymphomas. Stable
cell lines were generated from lymphomas from sick control
Em-Myc or p53-deﬁcient Em-Myc mice. Upon in vitro treat-
ment of control Em-Myc and Em-Myc/p53
 /  lymphoma cell
lines with 0.2mg/ml etoposide for 3, 6 or 8h, only negligible
induction of Bad, Bid and Bmf was observed (Figure 6a). Bim
mRNA, concordant with our previous ﬁndings,
21 was
markedly induced in Em-Myc lymphoma cell lines and was
signiﬁcantly less pronounced in Em-Myc lymphoma cell lines
lacking p53. Similarly, Bik mRNA was upregulated, albeit at
slightly lower magnitude than Bim (B4-fold vs B8-fold at 6h,
respectively; Figure 6a). However, in contrast to Bim, Bik
mRNA induction (B3-fold at 6h and B7-fold at 8h) was also
upregulated at similar levels in Em-Myc/p53
 /  lymphoma
cell lines (Figure 6a), demonstrating that this transcriptional
induction is p53-independent.
Loss of Bik alone, or in combination with Noxa loss does
not render El-Myc lymphoma cells resistant to DNA-
damaging drug-induced killing. Although Bik mRNA is
induced in Em-Myc lymphoma cells following etoposide
treatment, we have shown previously that Em-Myc/Bik
 / 
lymphoma cell lines display sensitivity to etoposide, compar-
able to that of conventional Em-Myc lymphoma cell lines.
21
The potential for important co-operation between BIK and
other BH3-only proteins could not be excluded. We therefore
investigated the possible co-operation between BIK and
NOXA in DNA damage-induced killing of lymphoma cells.
Analysis of stable cell lines from four independent lympho-
mas arising in Em-Myc/Bik
 / Noxa
 /  mice revealed that
concomitant loss of BIK and NOXA did not afford signiﬁcant
protection from etoposide-induced killing (Figure 6b).
The role of Bik in DNA-damaging drug-induced apoptosis
was further assessed in vivo by transplanting primary
lymphomas into immuno-competent C57BL/6-recipient mice.
Once tumours became palpable, the mice were treated with
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Figure4 CombinedlossofBikandNoxadoesnotincreasetheseverityofdiseaseinEm-Myctransgenicmice.Photomicrographs(magniﬁcation  200)ofhaematoxylin-
and eosin-stained parafﬁn-embedded sections of lymph nodes, spleen, liver and kidneys from representative lymphoma-burdened sick control Em-Myc,E m-Myc/Bik
 /  and
Em-Myc/Bik
 / Noxa
 /  mice (one mouse per genotype shown)
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Cell Death and DiseaseCTX at either 200 or 300mg/kg body weight (the maximum
tolerated dose
21). Kaplan–Meier survival curves for mice
bearing control Em-Myc (n¼17), Em-Myc/Bik
 /  (n¼7), Em-
Myc/Bik
 / Noxa
 /  (n¼6) and Em-Myc (p53 mutant)
(n¼4) lymphomas treated with CTX are shown in Figure 6c.
For mice bearing control Em-Myc lymphomas that were
treated with either 200 or 300mg/kg body weight of CTX, a
median survival of 102 or 176 days post treatment was
observed, respectively, compared with only 5 days for control
Em-Myc lymphoma-bearing mice treated with vehicle alone
(Supplementary Table 2). A similar prolongation in survival
was observed following CTX treatment of mice bearing
Em-Myc/Bik
 /  (80 and 86 days for 200 or 300mg/kg body
weight of CTX, respectively) or Em-Myc/Bik
 / Noxa
 / 
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Figure 5 Bik loss, with or without Noxa loss, does not alter the pressure for selection for a mutated p53 pathway during Em-Myc-induced lymphoma development.
(a) Genomic PCR analysis of the Ink4a/Arf locus revealed that none of the Em-Myc/Bik
 /  or Em-Myc/Bik
 / Noxa
 /  lymphomas examined had a deletion in this gene.
Controls include an Em-Myc lymphoma cell line known to contain a deletion in the Ink4a/Arf locus (denoted as –ve) and an Em-Myc lymphoma known to retain the Ink4a/Arf
locus(denotedas þve).(b)Representativewesternblotsofp19
ARF,p53andb-ACTIN(loadingcontrol)inrandomlyselectedcontrolEm-Myc,E m-Myc/Bik
 /  andEm-Myc/
Bik
 / Noxa
 /  lymphomas. Extracts from MEF immortalised with SV40 large T antigen were included as a positive control for p19
ARF and p53 overexpression. The Em-
Myc lymphoma #280 was included on each blot as a reference lymphoma. (c) A graphical representation of the proportions of Em-Myc, Em-Myc/Bik
 /  and Em-Myc/Bik
 /
 Noxa
 /  lymphomasanalysedwithamutatedp19
ARF–p53pathway,asdeterminedbywesternblottingforp53,p19
ARFprotein.(d)Schematicdiagramdepictingactivation
of the p19
ARF–p53 pathway by c-MYC and the negative feedback loop that exists between p53 and p19
ARF
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Cell Death and Disease(58 and 175 days for 200 or 300mg/kg body weight of CTX,
respectively) lymphomas, compared with only 2 to 8 days for
mice treated with vehicle alone (Supplementary Table 2).
The in vivo survival data were analysed using Cox
proportional hazards models, taking into account the correla-
tion between recipient mice. No signiﬁcant difference post-
CTX treatment was observed between the survival of mice
bearing control Em-Myc (blue curves) and Em-Myc/Bik
 / 
(orange curves) lymphomas (P¼0.869 for 200mg/kg body
weight CTX, P¼0.336 for 300mg/kg body weight CTX) or
between the survival of mice bearing control Em-Myc (blue
curves) and Em-Myc/Bik
 / Noxa
 /  (green curves) lym-
phomas (P¼0.637 for 200mg/kg body weight CTX;
P¼0.212 for 300mg/kg body weight CTX) (Figure 6c).
As expected, Em-Myc lymphomas with a mutated p53–
p19
ARF pathway (red curves) displayed profound resistance
to CTX and mice bearing such tumours died rapidly following
treatment. Consistent with the in vitro data, neither lympho-
mas lacking Bik alone, nor those lacking both Bik and Noxa,
displayed an increase in resistance to CTX treatment in vivo
compared with lymphomas with endogenous levels of Bik
and Noxa.
Discussion
Bik-deﬁcient mice develop normally with a normal lifespan.
7
Non-transformed haematopoietic cells and ﬁbroblasts from
these mice respond normally to various apoptotic stimuli,
including DNA damage.
7 Although these results would
suggest functional redundancy between BIK and other pro-
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Figure 6 Bik levels are augmented in Em-Myc lymphoma cells in response to DNA damage inducing anti-cancer drugs but loss of Bik does not render these lymphoma
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individual experiments with three independent lymphoma cell lines for each genotype. (b) Cell lines derived from independent Em-Myc lymphomas of the indicatedgenotypes
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to CTX (200 or 300mg/kg body weight) treatment in vivo. Kaplan–Meier survival curves of mice transplanted (day 0) with lymphomas of the indicated genotypes and
treated, once lymphomas became palpable at around day 12. Data were pooled from 4–16 independent lymphomas per genotype with 5–10 recipient mice per
treatment per independent lymphomas. No signiﬁcant differences in survival were observed between mice bearing Em-Myc/Bik
 / ,E m-Myc/Bik
 / Noxa
 /  or control
Em-Myc lymphomas
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Cell Death and Diseaseapoptotic BH3-only proteins, BIK has been proposed to
function as a tumour suppressor in several human cancers,
including some lymphoid malignancies.
8
Apoptosis triggered by c-Myc overexpression is regulated
by the BCL-2 protein family
30,31 and is thought to impose a
major barrier to MYC-induced lymphoma development.
Accordingly, overexpression of pro-survival BCL-2
32 or loss
of BH3-only proteins that have potent killing capacity, such as
BIM
23,28 and PUMA
22,24 can signiﬁcantly accelerate MYC-
induced lymphomagenesis in mice. A recent study showed
that loss of the more ‘selective’ binders, and therefore less
potent BH3-only proteins, BMF and BAD, can also accelerate
Em-Myc-driven lymphomagenesis.
25 These data are some-
what surprising given that theoretically, the promiscuous BIM
or PUMA could adequately compensate for loss of either BMF
or BAD. These ﬁndings indicate that the role of selective BH3-
only proteins in tumour suppression may not simply be
redundant to the functions of ‘potent’ BH3-only proteins and
the control of survival of cells undergoing neoplastic transfor-
mation is not solely dictated by the sequestration of pro-
survival BCL-2 family proteins.
33 We therefore reasoned that
BIKmightalsoconstraintumourdevelopmentinthecontextof
c-MYC overexpression.
BikmRNAexpressionlevelsweremodestlyelevatedinpre-
leukaemic, B-lymphoid cells from pre-malignant Em-Myc mice
compared with those from control (WT) mice. Moreover,
lymphomacellsfromsickEm-Mycmicealsoexpressedreadily
detectable levels of Bik mRNA. These observations support
the notion that BIK may have a role in suppression of Em-Myc-
induced lymphomagenesis. Induction of apoptosis by c-MYC
overexpression is attributable in part to activation of the
p19
ARF– p53 pathway, in which p19
ARF upregulation prevents
the degradation of p53 by sequestration of the ubiquitin ligase
MDM2.
27,34 The link between Bik levels and p53, however, is
controversial. Although putative p53 binding sites have been
identiﬁed in the promoter of the Bik gene
35 and ectopic
overexpression of p53 has been shown to robustly induce Bik
expression,
17 a p53 response could not be detected in
promoter/reporter assays.
17,18 c-MYC overexpression can,
however, also induce apoptosis independent of p53
18,27 and
thus, the elevation of Bik we observed may be critical for
apoptosis induction independent of p53.
Despite evidence of loss of BIK expression in human
tumours,
8 in the Em-Myc transgenic mouse model, loss of BIK
was insufﬁcient to accelerate lymphoma onset or increase
disease severity. Time to tumour morbidity (when animals
havetobekilled)hasbeendemonstratedtodifferaccordingto
immunophenotype (sIgM
  pre-B or sIgM
þ B cell) of
lymphomas in Em-Myc mice lacking certain BH3-only genes.
For example, loss of BIM, PUMA, BMF or BAD accelerated
development of Em-Myc B-cell lymphoma while the onset of
pre-B lymphoma was unaltered.
22,23,25 Moreover, loss of
NOXA delayed the onset of Em-Myc pre-B lymphomas but not
Em-Myc B-cell lymphomas.
22 In comparison, BIK deﬁciency
had no impact on pre-B or B-cell Em-Myc lymphoma
development, implying that BIK may have overlapping
functions with other BH3-only proteins. BIK may still be a
barrier to tumour development in other cell types, both
haematological and nonhaematological, or in tumourigenesis
driven by distinct oncogenic lesions (unrelated to c-MYC
overexpression). Alternatively, the lack of effect on tumour-
igenesis may reﬂect BIK’s ability to sequester only select pro-
survival BCL-2 family proteins.
2,26 Therefore, the disturbance
of the overall balance between pro-apoptotic and anti-
apoptotic BCL-2 family members caused by BIK loss would
be relatively minor, as loss of BIK can theoretically be
compensated for by several other (selective binding) pro-
apoptotic BH3-only proteins (such as BMF and BAD) and loss
of BIK would not be expected to impact on inhibition of either
MCL-1 or A1.
The lack of protection of Em-Myc lymphomas from DNA-
damaging drug-induced killing conferredbyloss of BIK stands
in contrast to studies in which ectopic overexpression of BIK
was used to potently induce apoptosis in tumour-derived cell
lines.
5,6,11,12,14 Overexpression may allow BIK to artiﬁcially
interact with and inhibit a wider array of pro-survival BCL-2
proteins
2,5,6 than does endogenous BIK, expressed under
physiological conditions. Nonetheless, it is curious that we
and others
19,20 have observed a modest induction of Bik
following DNA damage, independent of p53. As its loss had
little impact on the apoptotic response of lymphoma cells, it is
unclear whether Bik induction contributes to apoptosis
induction in this setting. The p53-independent upregulation
of Bik may function to amplify the response to DNA-damaging
drugs observed in Em-Myc lymphomas that is elicited by the
major p53-dependent apoptosis inducers, PUMA and NOXA.
Enforced co-expression of BIK and NOXA can cooperate
potently in killing mouse embryonic ﬁbroblasts (MEFs)
2 and in
H1299 cells, to synergise in inducing BAX activation and
cytochrome c release from mitochondria.
15 This cooperative
action is presumably due to the complementary nature of their
binding abilities to pro-survival BCL-2 family members.
2 BIK
and NOXA together can theoretically complement one
another to allow sufﬁcient neutralisation of all pro-survival
BCL-2-like proteins in a cell to promote more potent apoptosis
inductionthanwouldbepossiblewithsoleexpressionofeither
protein. We have found, however, that a combined deﬁciency
in BIK and NOXA is not sufﬁcient for acceleration of Em-Myc-
induced lymphoma development or to increase resistance of
Em-Myc lymphoma cells to DNA-damaging drug-induced
apoptosis indicating that other BH3-only proteins, such as
potent family members, PUMA and BIM, can still adequately
compensate for their loss. Loss of both BIK and NOXA did not
signiﬁcantly alter the transcription of other pro-apoptotic BH3-
only genes, such as Bad, Bim, Puma and Bmf or pro-survival
genes, such as Bcl-2, Bcl-xl or Mcl-1, although alterations in
the post-transcriptional regulation of these BCL-2 family
members cannot be excluded.
Functionally relevant inhibition of the apoptotic signalling
pathway downstream of p53, such as that afforded by loss of
PUMA or by the combined loss of PUMA and NOXA, have
been shown to diminish the pressure for p19
ARF– p53
pathway mutations in c-MYC overexpression-driven lympho-
mas,
22,24 as has loss of BIM
23 or BMF (but not loss of BAD).
25
Deﬁciency in BIK alone was not able to diminish the selection
for loss of p53 function, indicating that loss of BIK cannot
compensate for loss of p53. This indicates that the levels of
the more potent (promiscuous binding) BH3-only proteins
PUMA and BIM are sufﬁcient in Em-Myc transgenic pre-B/
B-lymphoid cells to delay neoplastic progression.
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Cell Death and DiseaseCollectively, studies of BH3-only gene deletion in the
Em-Myc lymphoma model highlight the intricacies of apoptotic
regulation in response to oncogene activation and DNA
damage. The life or death fate of cells undergoing neoplastic
progressionoroftransformedcancercellsfollowingtreatment
with anti-cancer drugs must not simply be governed by the
overall balance of pro- and anti-apoptotic BCL-2 family
members, but instead requires the activation of distinct BH3-
only proteins for apoptosis induction in a cell-type- and
stimulus-speciﬁc manner. Thus Bik, even in combination with
Noxa, is not a potent suppressor of c-Myc-driven tumourigen-
esis or critical for chemotherapeutic drug-induced killing of
Myc-driven tumours.
Materials and Methods
Materials. Etoposide and CTX were purchased from Sigma (Castle Hill, NSW,
Australia), QVD-OPH (MP Biomedicals, Aurora, OH, USA) was used in
experiments at a ﬁnal concentration of 25mM.
Experimental animals. All experiments with mice were performed according
to the guidelines of The Walter and Eliza Hall Institute of Medical Research Animal
Ethics Committee. The Em-Myc transgenic mice expressing the c-Myc oncogene under
the control of the immunoglobulin heavy chain gene enhancer (Em)
9,10 have been
backcrossed with C57BL/6 mice for 420 generations. The origins of the Noxa
 / ,
36
Bik
 / 7 and p53
 /  37 mice (all on a C57BL/6 background) have been described.
The former two strains were generated on an inbred C57BL/6 background using C57BL/
6-derived ES cells; the p53
 /  mice were generated on a mixed C57BL/6 129SV
background, using 129SV-derived ES cells, but were backcrossed with C57BL/6 mice
for 410 generations. Em-Myc transgenic males were crossed with p53
 /  or p53
þ/
  females to generate Em-myc/p53
þ/  offspring and with Noxa
 /  or Bik
 / 
females to produce Em-Myc/Noxa
þ/  or Em-Myc/Bik
þ/  males, which were
then crossed with Noxa
 /  or Bik
 /  females to yield Em-Myc/Noxa
 /  or
Em-Myc/Bik
 /  progeny, respectively, in separate breedings. Em-Myc/Noxa
 / 
males were crossed with Bik
 / Noxa
 /  double knockout females to generate
Em-Myc/Bik
þ/ Noxa
 /  males, which were then bred to Bik
 / Noxa
 / 
females to yield Em-Myc/Bik
 / Noxa
 /  mice.
El-Myc lymphomas and lymphoma cell lines. Em-Myc lymphomas
were deﬁned by ﬂow cytometry as either pre-B (B220
þ sIg
 ) or B-cell
lymphomas (B220
þ sIgM
þ). Lymphoma cells were used for either transplantation
into C57BL/6-recipient mice for in vivo drug sensitivity analysis or for in vitro
culture to obtain stable lymphoma cell lines. Lymphoma cell lines were generated
by preparing single-cell suspensions from spleen, which were cultured at 371Ci n
a humidiﬁed 10% CO2 incubator in high-glucose Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% foetal calf serum (JRH Biosciences, Brooklyn,
VIC, Australia), 50mM 2-mercaptoethanol (Sigma) and 100mM asparagine
(Sigma) referred to as FMA.
Western blotting. Protein samples were size-fractionated by SDS-PAGE and
then blotted onto nitrocellulose (Invitrogen, Grand Island, NY, USA) membranes.
Membranes were blocked with 5% non-fat dry milk (Devondale, Melbourne, VIC,
Australia) in PBS with 0.1% Tween 20 (Sigma) and then probed with antibodies
against p53 (CM5, Novacastra, North Ryde, NSW, Australia), p19
ARF (AbCam,
W a t e r l o o ,N S W ,A u s t r a l i a )a n db-ACTIN (clone AC-74, Sigma; used as a loading
control). Detection was performed with HRP-conjugated secondary antibodies and
enhanced chemiluminescence (Amersham Biosciences, Castle Hill, NSW, Australia).
Quantitative reverse transcription (qRT)-PCR. Cells were given a
DNA damage insult (etoposide) in the presence of QVD-OPH to prevent terminal
cellular destruction, and RNA was isolated at speciﬁc time points following
treatment. Total RNA was extracted from 0.5–1 10
6 cells using the TRIzol
Reagent (Invitrogen) according to the manufacturer’s instructions. 0.5–1mgo f
total RNA was converted to cDNA using the High Capacity RNA to cDNA kit
(Applied Biosystems, Mulgrave, VIC, Australia). For quantitative analysis, the
resulting cDNA was subjected to PCR in 10ml reaction volumes using Taqman
Universal PCR Master Mix (Applied Biosystems) with Taqman Gene Expression
Assays (Applied Biosystems) and assessed on an ABI-PRISM 7900 thermal cycler
(Applied Biosystems). b-Actin served as an endogenous normalisation control.
Data analyses were performed by the comparative threshold cycle method.
Cell death assays. Em-Myc lymphoma cells were cultured in FMA at a
concentration of 25000–50000 cells per well in 96-well ﬂat bottom microtiter plates
(Falcon, North Ryde, NSW, Australia). Cells were exposed to etoposide/VP16
(Pﬁzer, West Ryde, NSW, Australia) (1, 0.2 or 0.04mg/ml) for 6 or 24h. Cell death
was assessed by ﬂow cytometric analysis after staining with propidium iodide (PI;
2mg/ml) and annexin V-FITC (0.3mg/ml). The extent of apoptosis induced
speciﬁcally by treatment with a DNA damage inducing chemotherapeutic drug
(percent speciﬁc apoptosis) was calculated using the following equation: [%
induced apoptosis – (% spontaneous apoptosis/100 – % spontaneous apoptosis)].
Each independent Em-Myc lymphoma-derived cell line was analysed in at least
three independent experiments.
In vivo lymphoma cell survival analysis post treatment with
DNA-damaging drugs. Six- to 8-week-old C57BL/6 female mice were
injected (i.v.) on day 0 with 2 10
6 Em-Myc lymphoma cells. Mice were treated
with CTX (200–300mg/kg) or vehicle alone when their spleens became palpable
(usually 10–16 days post tumour injection). Mice were culled when deemed unwell
(lethargy, tremor, hind-leg paralysis, 45% weight loss, palpable tumour) in
accordance with ethical guidelines, or in the absence of symptoms of lymphoma at
180 days post treatment (when these experiments were terminated).
Analysis of cdkn2a locus. Multiplex PCR analysis of genomic DNA
extracted from lymphoma cells for the cdkn2a (p16
Ink4a/p19
Arf) locus was
performed to reveal gross deletions, using exon-speciﬁc primers for a-actin, exons
2, 1a and 1b as previously described.
38,39
Histology. Soft tissues (spleen, lymph nodes, liver, kidney, heart, lung,
thymus) and sternum were ﬁxed in 10% buffered formalin. Tissues were
embedded in parafﬁn, sectioned and stained using haematoxylin and eosin.
Statistical analysis. Prism (GraphPad Prism, GraphPad Software Inc.,
La Jolla, CA, USA), Stata 9.2 (StataCorp., College Station, TX, USA) and R
(www.r-project.org) software were used for statistical analysis. Two-group
comparisons of leukaemic burden, lymphocyte counts and spleen weights used
two-tailed t-tests assuming equal variances.
Survival data were plotted using Kaplan–Meier curves. Differences in survival
time to tumour-related deaths of Em-Myc mice of various genotypes were tested
using log-rank tests (each independent lymphoma analysed separately). P values
o 0.05 were considered to indicate statistical signiﬁcance.
The survival data on lymphoma-burdened mice following in vivo treatment with
CTX involved two-levels of biological replication, with many independently derived
lymphomas of different genotypes and varying numbers of recipient mice per
treatment arm per independent lymphoma (Supplementary Table 2), meaning that
the survival times of recipient mice burdened with the same lymphoma were
statisticallydependent.To producetheKaplan–Meier plotsin Figure6c, the median
survival time was calculated separately for censored and non-censored mice for
each independent lymphoma. The resulting Kaplan–Meier curves correspond to
independent lymphoma rather than to recipient mice, and hence are statistically
independent. To test whether the survival times of the different genotypes were
signiﬁcantlydifferent,Coxproportionalhazardsregressionmodels(Cox,1972)were
ﬁtted. The correlations between recipient mice were taken into account using a
robust sandwich estimator, implemented as method stcox cluster in Stata 9.2, to
estimate S.E. from the Cox model.
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